neurofit@neurofit.com

for CNS and PNS disorders

+33(0)3 88 65 16 06

Validated in vitro and in vivo disease and safety models for drug screening

PARKINSON'S disease

  • Parkinson’s disease (PD) is a neurodegenerative disease which involves a selective degeneration of nigrostriatal dopaminergic neurons characterized by various motor and non-motor disorders. Neurofit offers various cellular and animal models to evaluate the neuroprotective effect of your compounds.


    MPP+ and 6-OHDA

    6-hydroxydopamine (6-OHDA) is a neurotoxin widely used in lab animals to produce striatal dopamine depletion.
    MPP+ is the active in-vivo metabolite of MPTP causing selective degeneration of nigrostriatal dopaminergic (DA) neurons in the PD.
    Similarly to the in-vivo situation, MPP+ induces a selective death of DA in primary cultures of rat mesencephalic neurons. Thus, MPP+ intoxication of mesencephalic neuronal culture appears as a relevant and a cost-effective alternative to the in-vivo experiments for the evaluation of new test compounds with potential beneficial effect on PD.

  • Compound testing


    Compound testing addresses the ability of test compounds to inhibit MPP+ or 6-OHDA - induced cell damage in mesencephalic neuron cultures as assessed by immunostainting of tyrosine hydroxylase neurons.
  • Endpoints


    Neurotrophin pathways
    Caspase pathway
    Inhibition of oxidative stress
  • Dose response toxicity of MPP+ and 6-OHDA on primary cultures of mesencephalic neurons


  • Reduced number of TH positive neurons () and cell viability (MTT assay, ) in mesencephalic neuron culture in response to increasing concentration of MPP+.

  • Reduced number of TH positive neurons () and cell viability (MTT assay, ) in mesencephalic neuron culture in response to increasing concentration of 6-OHDA.
  • Stimulation of neurotrophin pathways :

  • Prevention of MPP+ -induced dopaminergic neurons death
    by pretreatment with mixture of BDNF-GDNF.
  • Prevention of 6-OHDA-induced dopaminergic neurons death
    by pretreatment with mixture of BDNF-GDNF.

  • Inhibition of caspase pathway :

  • Prevention of MPP+ -induced dopaminergic neurons death
    by pretreatment with z-VAD-fmk, a caspase inhibitor.
  • Prevention of 6-OHDA–induced dopaminergic neurons death
    by pretreatment with z-VAD-fmk, a caspase inhibitor.

  • Inhibition of oxidative stress :

  • Prevention of MPP+ -induced dopaminergic neurons death
    by pretreatment with the antioxidant N-acetyl-cystein.
  • Prevention of 6-OHDA-induced dopaminergic neurons death
    by pretreatment with the antioxidant N-acetyl-cystein.

You could also be interested in



  • Viability and survival tests

    The survival test exploits the natural tendency of cells to die in culture and is therefore used to assess the neuroprotective properties of your compounds.


    Brain inflammation

    Neuroinflammation is a critical process in different neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, MS ...

  • Haldol

    Catalepsy is a well-known symptom of Parkinson's disease.